LATEST DEVELOPMENTS

In 2022, Germany’s Evonik partnered with US’ 3D printed pharmaceutical firm Laxxon Medical to bring the mass production of 3D printed tablets closer to reality. The aim of the partnership is to improve drug delivery for patients while also advancing the commercialization of 3D printed pharmaceuticals

In 2021, UK’s University of East Anglia (UEA) researchers investigated technology to 3D ‘print’ pills. The team, including Dr Andy Gleadall and Prof. Richard Bibb at Loughborough University, identified a new additive manufacturing method to allow the 3D printing of medicine in highly porous structures, which can be used to regulate the rate of drug release from the medicine to the body when taken orally

In 2020, UK’s Fabrx, a specialist biotech company, developed M3dimakertm, the world’s first 3D printer for the production of personalised medicines

In 2020, Chinese 3D printing technology startup Triastek raised $15 million in Series A funding to accelerate the research and development of its 3D printed drugs

In 2020, South Korean pharmaceutical company HK inno.N announced plans to use artificial 3D printed skin to test new autoimmune and skin disorder drugs